Cargando…
Who approves/pays for additional monitoring?
Major considerations in the provision of healthcare are availability, affordability, accessibility, and appropriateness, especially in the setting of heart failure where disease burden is growing, developments have been rapid and newer biomarkers, diagnostic and imaging techniques, monitoring system...
Autores principales: | Rosano, Giuseppe M C, Spoletini, Ilaria, Vitale, Cristiana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937509/ https://www.ncbi.nlm.nih.gov/pubmed/31908621 http://dx.doi.org/10.1093/eurheartj/suz228 |
Ejemplares similares
-
Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
por: Rosano, Giuseppe MC, et al.
Publicado: (2019) -
Monitoring functional capacity in heart failure
por: Piepoli, Massimo F, et al.
Publicado: (2019) -
Monitoring of biomarkers in heart failure
por: Spoletini, Ilaria, et al.
Publicado: (2019) -
Renal function, electrolytes, and congestion monitoring in heart failure
por: Rossignol, Patrick, et al.
Publicado: (2019) -
Implantable devices for heart failure monitoring: the CardioMEMS™ system
por: Volterrani, Maurizio, et al.
Publicado: (2019)